Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.
An exploratory analysis of tailored dosing in the PANTHER trial demonstrated that obese patients (BMI≥30) treated with tailored dose-dense chemotherapy had improved breast cancer relapse-free survival (BCRFS) compared to non-obese ones (BMI<30) (HR = 0.51 [95% CI 0.30-0.89]; p=0.02). Furthermore, the tailored dose-dense chemotherapy was associated with improved BCRFS compared to standard anthracycline/taxane containing regimen only in obese patients (HR=0.49 [95%CI 0.26-0.90]; p=0.022, test for interaction p=0.175). There were no differences in terms of toxicity between the BMI groups. Hence, the use of tailored dose-dense regimen as adjuvant chemotherapy can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.
Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2018 Oct 24 [Epub ahead of print].
Link in PubMed
GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440